Can-fite announces final data analysis from phase ii nash study: highly significant and sustained reduction in liver fat volume throughout study period

Can-fite biopharma ltd. (nyse american: canf) (tase:cfbi), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addre

AXDX Ratings Summary

AXDX Quant Ranking